Beijing: By 2027, establish an industrial ecological system integrating "artificial intelligence + pharmaceuticals and health" innovation and application in Beijing.

The "Beijing Accelerating Promoting the Innovation and Development Action Plan for Artificial Intelligence + Medicine and Health" was released on the 3rd. It proposes to give full play to Beijing's outstanding advantages in artificial intelligence technology origination, the convergence of top medical resources, and the high enrichment of health data. With application-driven as the guiding principle, it will coordinate the advancement of cutting-edge technology innovation, data aggregation and circulation, deep empowerment of applications, and the cultivation of industrial ecology, stimulating the potential for innovation and development of "Artificial Intelligence + Medicine and Health". By 2027, it aims to build a "Artificial Intelligence + Medicine and Health" innovation and application dual industrial ecosystem in Beijing, basically forming an internationally influential "Artificial Intelligence + Medicine and Health" innovation origination center, application highland, and industrial cluster area. It will adhere to innovation-driven, strengthen technology origination, promote innovation paradigm change, breakthroughs in key technologies, and innovation research and development of products. It will achieve a number of internationally leading innovative results, produce a number of new technologies, tools, and models for "Artificial Intelligence + Medicine and Health", and commercialize more than 30 core technologies and innovative products. It will highlight scenario-driven, deepen application implementation, focus on promoting the application of artificial intelligence technology in the research and development, production, and other links of innovative pharmaceutical and medical equipment products, achieve digitalization upgrade in the pharmaceutical and health industry, and use artificial intelligence technology to accelerate the entry of no less than 20 innovative pharmaceutical and medical equipment research into clinical trial phase, and accelerate the application of artificial intelligence technology in no less than 10 scenarios in medical services, convalescence services, medical science education, medical health insurance, and public health fields.